The Association of Clinical Research Organizations (ACRO), which represents the clinical outsourcing industry, announced its leadership role in the recently formed Clinical Trial Transformation Initiative (CTTI). The goal of the CTTI is to modernize the mechanics of clinical trials and to increase their efficiency and productivity.
The CTTI was established by the US Food and Drug Administration (FDA) in collaboration with Duke University as part of the FDA’s Critical Path Initiative. Alberto Grignolo, PhD, Corporate Vice President and General Manager of PAREXEL Consulting, a business unit of PAREXEL International, will represent the association on the CTTI Executive Board, which is comprised of experts from the FDA, National Institutes of Health (NIH), academia, biopharmaceutical companies, CROs, and other organizations.
“CTTI has an important charge as it looks to establish models for clinical trial innovation in areas such as study design, operating procedures, and metrics for evaluation,” said Grignolo. “I look forward to representing the CRO industry and working with the wide range of stakeholders involved to help make this initiative successful for all who participate in the clinical trial enterprise, including study participants, investigators, regulators, sponsors, and CROs.”
Release date: May 6, 2008
Source: Association of Clinical Research Organizations (ACRO)
Filed Under: Drug Discovery
